{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:59:06Z","timestamp":1788263946951,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40257-019-00493-z","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T10:08:39Z","timestamp":1576145319000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris"],"prefix":"10.1007","volume":"21","author":[{"given":"Dustin H.","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-520X","authenticated-orcid":false,"given":"Maryanne M.","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"issue":"4","key":"493_CR1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2265.1994.tb02483.x","volume":"40","author":"VA Randall","year":"1994","unstructured":"Randall VA. Androgens and human hair growth. Clin Endocrinol (Oxf). 1994;40(4):439\u201357.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"Suppl 4","key":"493_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0625.2004.00255.x","volume":"13","author":"CC Zouboulis","year":"2004","unstructured":"Zouboulis CC, Degitz K. Androgen action on human skin: from basic research to clinical significance. Exp Dermatol. 2004;13(Suppl 4):5\u201310.","journal-title":"Exp Dermatol."},{"issue":"7","key":"493_CR3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00403-012-1265-x","volume":"304","author":"J-J Lai","year":"2012","unstructured":"Lai J-J, Chang P, Lai K-P, Chen L, Chang C. The role of androgen and androgen receptor in the skin-related disorders. Arch Dermatol Res. 2012;304(7):499\u2013510.","journal-title":"Arch Dermatol Res."},{"issue":"5\u20136","key":"493_CR4","first-page":"230","volume":"54","author":"CC Zouboulis","year":"2000","unstructured":"Zouboulis CC. Human skin: an independent peripheral endocrine organ. Horm Res. 2000;54(5\u20136):230\u201342.","journal-title":"Horm Res."},{"issue":"2","key":"493_CR5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2007-961807","volume":"39","author":"CC Zouboulis","year":"2007","unstructured":"Zouboulis CC, Chen W-C, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res. 2007;39(2):85\u201395.","journal-title":"Horm Metab Res."},{"issue":"5","key":"493_CR6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/1523-1747.ep12472330","volume":"100","author":"T Liang","year":"1993","unstructured":"Liang T, Hoyer S, Yu R, et al. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 1993;100(5):663\u20136.","journal-title":"J Invest Dermatol."},{"issue":"7","key":"493_CR7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","volume":"28","author":"HV Heemers","year":"2007","unstructured":"Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778\u2013808.","journal-title":"Endocr Rev."},{"issue":"3","key":"493_CR8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1677\/joe.0.1330467","volume":"133","author":"R Choudhry","year":"1992","unstructured":"Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol. 1992;133(3):467\u201375.","journal-title":"J Endocrinol."},{"issue":"3","key":"493_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000246242","volume":"193","author":"W Chen","year":"1996","unstructured":"Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatol Basel Switz. 1996;193(3):177\u201384.","journal-title":"Dermatol Basel Switz."},{"issue":"2","key":"493_CR10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/derm.1.2.8472","volume":"1","author":"M Picardo","year":"2009","unstructured":"Picardo M, Ottaviani M, Camera E, Mastrofrancesco A. Sebaceous gland lipids. Dermatoendocrinol. 2009;1(2):68\u201371.","journal-title":"Dermatoendocrinol."},{"issue":"6","key":"493_CR11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1600-0625.2008.00725.x","volume":"17","author":"CC Zouboulis","year":"2008","unstructured":"Zouboulis CC, Baron JM, B\u00f6hm M, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol. 2008;17(6):542\u201351.","journal-title":"Exp Dermatol."},{"issue":"1","key":"493_CR12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/derm.3.1.13900","volume":"3","author":"E Makrantonaki","year":"2011","unstructured":"Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3(1):41\u20139.","journal-title":"Dermatoendocrinol."},{"issue":"1","key":"493_CR13","first-page":"44","volume":"13","author":"T Knor","year":"2005","unstructured":"Knor T. The pathogenesis of acne. Acta Dermatovenerol Croat. 2005;13(1):44\u20139.","journal-title":"Acta Dermatovenerol Croat."},{"issue":"S2","key":"493_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdv.15043","volume":"32","author":"B Dr\u00e9no","year":"2018","unstructured":"Dr\u00e9no B, P\u00e9castaings S, Corvec S, Veraldi S, Khammari A, Roques C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(S2):5\u201314.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"493_CR15","first-page":"100","volume":"11","author":"ME Stewart","year":"1992","unstructured":"Stewart ME. Sebaceous gland lipids. Semin Dermatol. 1992;11(2):100\u20135.","journal-title":"Semin Dermatol."},{"issue":"2 Pt 1","key":"493_CR16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0190-9622(86)70025-X","volume":"14","author":"DT Downing","year":"1986","unstructured":"Downing DT, Stewart ME, Wertz PW, Strauss JS. Essential fatty acids and acne. J Am Acad Dermatol. 1986;14(2 Pt 1):221\u20135.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"493_CR17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/1523-1747.ep12261252","volume":"56","author":"G Sansone","year":"1971","unstructured":"Sansone G, Reisner RM. Differential rates of conversion of testosterone to dihydrotestosterone in acne and in normal human skin: a possible pathogenic factor in acne. J Invest Dermatol. 1971;56(5):366\u201372.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"493_CR18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0190-9622(85)70067-9","volume":"12","author":"DP Lookingbill","year":"1985","unstructured":"Lookingbill DP, Horton R, Demers LM, Egan N, Marks JG, Santen RJ. Tissue production of androgens in women with acne. J Am Acad Dermatol. 1985;12(3):481\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"493_CR19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1529-8019.2008.00214.x","volume":"21","author":"VA Randall","year":"2008","unstructured":"Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314\u201328.","journal-title":"Dermatol Ther."},{"key":"493_CR20","first-page":"145","volume-title":"Androgens and antiandrogen therapy. Current topics in endocrinology","author":"RA Sawers","year":"1982","unstructured":"Sawers RA, Randall VA, Iqbal MJ. Studies on the clinical and endocrine aspects of antiandrogens. In: Jeffcoate SL, editor. Androgens and antiandrogen therapy. Current topics in endocrinology, vol. 1. Chichester: John Wiley; 1982. p. 145\u201368."},{"issue":"3","key":"493_CR21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1749-6632.1951.tb31959.x","volume":"53","author":"EL Reynolds","year":"1951","unstructured":"Reynolds EL. The appearance of adult patterns of body hair in man. Ann N Y Acad Sci. 1951;53(3):576\u201384.","journal-title":"Ann N Y Acad Sci."},{"issue":"3","key":"493_CR22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1749-6632.1951.tb31971.x","volume":"53","author":"JB Hamilton","year":"1951","unstructured":"Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53(3):708\u201328.","journal-title":"Ann N Y Acad Sci."},{"issue":"2","key":"493_CR23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0094-1298(20)30347-3","volume":"9","author":"N Orentreich","year":"1982","unstructured":"Orentreich N, Durr NP. Biology of scalp hair growth. Clin Plast Surg. 1982;9(2):197\u2013205.","journal-title":"Clin Plast Surg."},{"issue":"235","key":"493_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/adc.44.235.291","volume":"44","author":"WA Marshall","year":"1969","unstructured":"Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291\u2013303.","journal-title":"Arch Dis Child."},{"issue":"6","key":"493_CR25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1523-1747.1998.00224.x","volume":"110","author":"JA Ellis","year":"1998","unstructured":"Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol. 1998;110(6):849\u201353.","journal-title":"J Invest Dermatol."},{"key":"493_CR26","unstructured":"Otberg N, Shapiro J. Chapter 88. Hair Growth Disorders. Fitzpatrick\u2019s Dermatology in General\nMedicine. 8th ed. Access Medicine, McGraw-Hill Medical. New York, NY: The McGraw-Hill Companies; 2012. https:\/\/accessmedicine-mhmedical-com.ezp-prod1.hul.harvard.edu\/Content.aspx?bookId=392&sectionId=41138795. Accessed 6 Sep 2018."},{"key":"493_CR27","volume-title":"Disorders of hair growth: diagnosis and treatment","author":"EA Olsen","year":"2003","unstructured":"Olsen EA. Disorders of hair growth: diagnosis and treatment. 2nd ed. New York: McGraw-Hill, Medical Publishing Division; 2003.","edition":"2"},{"issue":"2","key":"493_CR28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1172\/JCI116665","volume":"92","author":"AE Thigpen","year":"1993","unstructured":"Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993;92(2):903\u201310.","journal-title":"J Clin Invest."},{"issue":"3","key":"493_CR29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/1523-1747.ep12335779","volume":"109","author":"ME Sawaya","year":"1997","unstructured":"Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296\u2013300.","journal-title":"J Invest Dermatol."},{"issue":"2","key":"493_CR30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1440-0960.2011.00745.x","volume":"52","author":"L Yip","year":"2011","unstructured":"Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know: Update on androgenetic alopecia. Australas J Dermatol. 2011;52(2):81\u20138.","journal-title":"Australas J Dermatol."},{"issue":"2","key":"493_CR31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaad.2004.04.008","volume":"52","author":"EA Olsen","year":"2005","unstructured":"Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301\u201311.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"493_CR32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijwd.2018.05.001","volume":"4","author":"G Fabbrocini","year":"2018","unstructured":"Fabbrocini G, Cantelli M, Masar\u00e0 A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4(4):203\u201311.","journal-title":"Int J Womens Dermatol."},{"issue":"1","key":"493_CR33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaad.2017.02.054","volume":"77","author":"A Adil","year":"2017","unstructured":"Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136\u2013141.e5.","journal-title":"J Am Acad Dermatol."},{"issue":"5 Pt 1","key":"493_CR34","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1067\/mjd.2000.107953","volume":"43","author":"VH Price","year":"2000","unstructured":"Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768\u201376.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"493_CR35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0015-0282(02)04551-X","volume":"79","author":"E Carmina","year":"2003","unstructured":"Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91\u20135.","journal-title":"Fertil Steril."},{"issue":"7","key":"493_CR36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/ijd.14370","volume":"58","author":"AC Hu","year":"2019","unstructured":"Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019;58(7):759\u201376.","journal-title":"Int J Dermatol."},{"issue":"4","key":"493_CR37","first-page":"457","volume":"17","author":"SW Lee","year":"2018","unstructured":"Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457\u201363.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"493_CR38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5414\/CP202467","volume":"54","author":"M Caserini","year":"2016","unstructured":"Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19\u201327.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"493_CR39","unstructured":"US Food and Drug Administration: Drug Databases. PROPECIA\u00ae (finasteride) Tablets, 1\u00a0mg drug insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020788s018lbl.pdf."},{"issue":"10","key":"493_CR40","doi-asserted-by":"crossref","first-page":"842","DOI":"10.5414\/CP202119","volume":"52","author":"M Caserini","year":"2014","unstructured":"Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842\u20139.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"12","key":"493_CR41","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/jdv.15171","volume":"32","author":"P Suchonwanit","year":"2018","unstructured":"Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257\u201363.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"493_CR42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40257-018-0387-0","volume":"20","author":"P Suchonwanit","year":"2019","unstructured":"Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147\u201353.","journal-title":"Am J Clin Dermatol."},{"issue":"3","key":"493_CR43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/09546639709160517","volume":"8","author":"GF Mazzarella","year":"1997","unstructured":"Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatol Treat. 1997;8(3):189\u201392.","journal-title":"J Dermatol Treat."},{"issue":"1","key":"493_CR44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0378-6323.45220","volume":"75","author":"Z Hajheydari","year":"2009","unstructured":"Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47\u201351.","journal-title":"Indian J Dermatol Venereol Leprol."},{"issue":"1","key":"493_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/2229-5178.148925","volume":"6","author":"BS Chandrashekar","year":"2015","unstructured":"Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17\u201320.","journal-title":"Indian Dermatol Online J."},{"issue":"10","key":"493_CR46","first-page":"1312","volume":"95","author":"C Tanglertsampan","year":"2012","unstructured":"Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil\/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312\u20136.","journal-title":"J Med Assoc Thai."},{"key":"493_CR47","unstructured":"Finasteride Treatment of Severe Nodulocystic Acne (NCT02502669). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02502669. Accessed 4 Jul 2019"},{"issue":"4","key":"493_CR48","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1159\/000017954","volume":"196","author":"C Pi\u00e9rard-Franchimont","year":"1998","unstructured":"Pi\u00e9rard-Franchimont C, De Doncker P, Cauwenbergh G, Pi\u00e9rard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474\u20137.","journal-title":"Dermatology."},{"key":"493_CR49","first-page":"301","volume":"243A","author":"FM Debruyne","year":"1987","unstructured":"Debruyne FM, Witjes FA. Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer. Prog Clin Biol Res. 1987;243A:301\u201313.","journal-title":"Prog Clin Biol Res."},{"issue":"1","key":"493_CR50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0306-9877(03)00264-0","volume":"62","author":"BS Hugo Perez","year":"2004","unstructured":"Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. 2004;62(1):112\u20135.","journal-title":"Med Hypotheses."},{"issue":"2","key":"493_CR51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0022-4731(89)90301-4","volume":"33","author":"M Ayub","year":"1989","unstructured":"Ayub M, Levell MJ. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J Steroid Biochem. 1989;33(2):251\u20135.","journal-title":"J Steroid Biochem."},{"issue":"8","key":"493_CR52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-2007-1003337","volume":"24","author":"C Eil","year":"1992","unstructured":"Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 1992;24(8):367\u201370.","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab."},{"key":"493_CR53","unstructured":"NIZORAL\u00ae (KETOCONAZOLE) 2% SHAMPOO package insert from Janssen Pharmaceuticals. October 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019927s032lbl.pdf."},{"issue":"6","key":"493_CR54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archderm.1986.01660180029008","volume":"122","author":"P Ghetti","year":"1986","unstructured":"Ghetti P, Patrone P, Tosti A. Ketoconazole in the Treatment of Acne in Women. Arch Dermatol. 1986;122(6):629\u2013629.","journal-title":"Arch Dermatol."},{"issue":"4","key":"493_CR55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1530\/eje.0.1300333","volume":"130","author":"AJ Vidal-Puig","year":"1994","unstructured":"Vidal-Puig AJ, Mu\u00f1oz-Torres M, J\u00f3dar-Gimeno E, et al. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol. 1994;130(4):333\u20138.","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"493_CR56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jcem-71-2-335","volume":"71","author":"S Venturoli","year":"1990","unstructured":"Venturoli S, Fabbri R, Dal Prato L, et al. Ketoconazole therapy for women with acne and\/or hirsutism. J Clin Endocrinol Metab. 1990;71(2):335\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"493_CR57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1348-0421.12464","volume":"61","author":"M Unno","year":"2017","unstructured":"Unno M, Cho O, Sugita T. Inhibition of Propionibacterium acnes lipase activity by the antifungal agent ketoconazole. Microbiol Immunol. 2017;61(1):42\u20134.","journal-title":"Microbiol Immunol."},{"issue":"8","key":"493_CR58","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/1346-8138.13245","volume":"43","author":"N Akaza","year":"2016","unstructured":"Akaza N, Akamatsu H, Numata S, et al. Microorganisms inhabiting follicular contents of facial acne are not only Propionibacterium but also Malassezia spp. J Dermatol. 2016;43(8):906\u201311.","journal-title":"J Dermatol."},{"key":"493_CR59","unstructured":"Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula\u00ae (Clascoterone) in Treating Androgenetic Alopecia. Cassiopea. 16 Apr 2019. http:\/\/www.cassiopea.com\/news-and-media\/press-releases\/yr-2019\/190416.aspx. Accessed 5 Jul 2019."},{"key":"493_CR60","unstructured":"Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety Study Evaluating Winlevi\u00ae (Clascoterone) Topical Cream for Treatment up to 1 Year. Cassiopea. 26 Mar 2019. http:\/\/www.cassiopea.com\/news-and-media\/press-releases\/yr-2019\/190326.aspx. Accessed 5 Jul 2019."},{"issue":"5","key":"493_CR61","first-page":"412","volume":"18","author":"C Rosette","year":"2019","unstructured":"Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol.\n2019;18(5):412\u20138.","journal-title":"J Drugs Dermatol."},{"issue":"2","key":"493_CR62","first-page":"197","volume":"18","author":"C Rosette","year":"2019","unstructured":"Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M. Cortexolone 17\u03b1-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197\u2013201.","journal-title":"J Drugs Dermatol."},{"issue":"6","key":"493_CR63","first-page":"570","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, Cartwright M. A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects With facial acne. J Drugs Dermatol. 2019;18(6):570.","journal-title":"J Drugs Dermatol."},{"key":"493_CR64","unstructured":"Cassiopea announces attainment of all primary and secondary endpoints and highly satisfactory safety data in its Phase 3 for Winlevi (Clascoterone) cream in Treating Acne. Cassiopea. 18 Oct 2018. http:\/\/www.cassiopea.com\/news-and-media\/press-releases\/yr-2018\/181018.aspx. Accessed 5 Jul 2019."},{"issue":"6","key":"493_CR65","first-page":"563","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.","journal-title":"J Drugs Dermatol."},{"key":"493_CR66","unstructured":"A study to evaluate the safety and efficacy of CB-03-01 Cream, 1% in subjects with facial acne vulgaris (NCT02608450). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02608450.Accessed 5 Jul 2019"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00493-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T19:26:45Z","timestamp":1607628405000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00493-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["493"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00493-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"12 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Maryanne Senna is a member of the scientific advisory board of Cassiopea. Dustin H. Marks, Sonya Prasad, Brianna De Souza, and Laura J. Burns have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}